Cellectis shares fall on pivot to in vivo gene editing
Cellectis said it is pivoting away from its legacy cell therapy pipeline to focus entirely on its in vivo gene editing business; shares were down 27% to $2.25 in premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.